| 1  | Vascular function and structure in veteran athletes following  |
|----|--|
| 2  | myocardial infarction  |
| 3  |  |
| 4  | Short title: vasculature in post-MI athletes   |
| 5  |  |
| 6  | Martijn F.H. Maessen MSc <sup>1</sup>  |
| 7  | Thijs M.H. Eijsvogels PhD <sup>1,2</sup>   |
| 8  | Bregina T.P. Hijmans-Kersten BSc <sup>1</sup>  |
| 9  | Ayla Grotens BSc <sup>1</sup>  |
| 10 | Tim H.A. Schreuder $PhD^3$   |
| 11 | Maria T.E. Hopman MD PhD <sup>1</sup>  |
| 12 | Dick H.J. Thijssen PhD <sup>1,2</sup>  |
| 13 |  |
| 14 | Affiliations:  |
| 15 | <sup>1</sup> Radboud Institute for Health Sciences, Department of Physiology, Radboud university medical       |
| 16 | center, Nijmegen, The Netherlands  |
| 17 | <sup>2</sup> Research Institute for Sports and Exercise Sciences, Liverpool John Moores University, Liverpool, |
| 18 | United Kingdom   |
| 19 | <sup>3</sup> Radboud Institute for Health Sciences, Department of Neurology, Radboud university medical        |
| 20 | center, Nijmegen, The Netherlands  |
| 21 |  |
| 22 | Total word count: 3681   |
| 23 | Word count abstract: 255   |
| 24 | Total number of Figures: 1   |
| 25 | Total number of Tables: 5  |
| 26 |  |
| 27 | Corresponding author:  |
| 28 | Prof. Maria Hopman, Radboud university medical center, P.O. Box 9101, 6500 HB Nijmegen, The                    |
| 29 | Netherlands. E-mail: Maria.Hopman@radboudumc.nl. Tel. (+31) (0)24 36 14200 Fax. (+31) (0)24                    |
| 30 | 36 68340   |
| 31 |  |
| 32 |  |
|    |  |

# 33 Abstract

Purpose. Despite athletes demonstrate a lower cardiovascular risk and superior vascular function compared to sedentary peers, they are not exempted from cardiac events (*i.e.*, myocardial infarction [MI]). The presence of a MI is associated with increased cardiovascular risk and impaired vascular function. We tested the hypothesis that lifelong exercise training in post-MI athletes, similar as in healthy controls, is associated with a superior peripheral vascular function and structure compared to a sedentary lifestyle in post-MI individuals.

Methods. We included 18 veteran (>20 years) athletes (ATH) and 18 sedentary controls (SED). To understand the impact of lifelong exercise training following MI, we included 20 veteran post-MI athletes (ATH+MI) and 19 sedentary post-MI controls (SED+MI). Participants underwent comprehensive assessment using vascular ultrasound (vascular stiffness, intima-media thickness (IMT), and endothelium (in)dependent mediated dilation). Lifetime Risk Score was calculated for a 30-year risk prediction of cardiovascular disease mortality of the participants.

Results. ATH demonstrated a lower vascular stiffness, and smaller femoral IMT compared to SED.
Vascular function and structure did not differ between ATH+MI and SED+MI. ATH (4.0%±5.1)
and ATH+MI (6.1%±3.7) had a significantly better lifetime risk score compared to their sedentary
peers (SED: 6.9%±3.7 and SED+MI: 9.3%±4.8). ATH+MI had no secondary events *versus* two
recurrent MI and six elective percutaneous coronary interventions within SED+MI (P<0.05).</li>

51 **Conclusion.** Although veteran post-MI athletes did not have a superior peripheral vascular function 52 and structure compared to their sedentary post-MI peers, benefits of lifelong exercise training in 53 veteran post-MI athletes relate to a better cardiovascular risk profile and lower occurrence of 54 secondary events.

55

56 Key Words: physical activity; endothelial function; cardiovascular risk; secondary prevention;
57 lifelong exercise training

# 58 INTRODUCTION

59 Exercise training is an effective strategy to lower the risk for cardiovascular diseases (21, 32, 36). The marked cardio-protective effects of exercise are in part explained via traditional risk factors, 60 such as a lower cholesterol level, blood pressure, and body mass index (19, 24). Additional benefits 61 of regular exercise training may relate to a direct effect on the arterial wall, leading to remodeling of 62 the arteries and improvement of endothelial function (35). For example, exercise training exerts its 63 64 benefits on the artery wall through repeated elevation in blood flow and vascular laminar shear 65 stress, which results in increased nitric oxide bioavailability, promotion of an antioxidant state, and improvement in vascular function and structure (8, 18). 66

67

68 Previous studies comparing athletes and sedentary controls consistently found that athletes have 69 higher vascular compliance and better vascular wall structure compared to sedentary controls (33, 35). Younger athletes also typically demonstrate outward remodelling, as evidenced by larger 70 71 conduit artery diameters and a larger resistance artery vascular bed (17). Some controversy is 72 present around the effects of regular exercise training on endothelial function of conduit arteries measured with the flow-mediated dilation (FMD) (6, 15, 16, 27, 40). Variation in FMD between 73 74 these studies may, at least partly, relate to structural remodelling in athletes (*i.e.*, larger diameter in athletes), that may contribute to a lower FMD (16). Exercise training is a widely accepted powerful 75 76 strategy to lower risk for future cardiovascular events, which is at least partly related to improved 77 vascular function (12).

78

Despite the vascular health benefits and reduction of cardiovascular risk with regular exercise (19, 24, 32, 36), veteran athletes are not exempted from acute coronary syndromes or myocardial infarction (22, 38). Previous work demonstrated that post-myocardial infarction (post-MI) patients have an impaired vascular function and structure compared to healthy peers (1, 10). Whether lifelong exercise training in post-MI patients may be associated with a preserved vascular function and structure is currently unknown. Therefore, we tested the hypothesis that lifelong exercise
training in post-MI athletes, similar as in healthy controls, is associated with a superior peripheral
vascular function and structure compared to a sedentary lifestyle in post-MI individuals.

87

# 88 **METHODS**

#### 89 **Participants**

In total, we included 75 middle-aged men. We included 36 healthy, asymptomatic men who were 90 divided over two groups: a) 18 veteran (>20 years) athletes (ATH) and b) 18 sedentary controls 91 92 (SED). To understand the role of a MI on the impact of lifelong exercise, we included 39 participants who were divided into: a) 20 veteran (>20 years) post-MI athletes (ATH+MI) and b) 19 93 94 sedentary post-MI controls (SED+MI). Athletes performed regular moderate or vigorous endurance 95 exercise training (e.g., running or cycling) for  $\geq 3.5$  hours per week for  $\geq 20$  years. Sedentary individuals performed habitual physical activities for  $\leq 2$  hours per week for  $\geq 20$  years. Smokers, 96 97 participants with diabetes mellitus type 1 or 2, and those not able to perform an incremental 98 maximal cycling test were excluded from participation in our study. The Local Committee on 99 Research Involving Human Subjects of the region Arnhem and Nijmegen approved the study and 100 the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. All 101 participants gave their written informed consent.

102

## 103 Lifelong exercise history

We asked the participants about their lifelong exercise history over five age-periods: I) 20-29 years, II) 30-39 years, III) 40-49 years, IV) 50-59 years, and V) >60 years. Three queries were asked per period: 1) type of activity (*e.g.*, running, cycling, etc., or nothing), 2) exercise time (hours) per activity per week, and (3) self-perceived exercise intensity (light, moderate, or vigorous) per activity. Based on Ainsworth's compendium of physical activities (2), we determined the corresponding metabolic equivalent of task (MET) score per activity. Based on the ACSM position stand (13), we defined moderate intensity activities between 3 and 5.9 MET, and vigorous intensity activities as  $\geq 6$  MET. Weekly exercise time was defined as the amount of time (in hours) spent on moderate and/or vigorous intensity exercise activities per week. The average weekly exercise time and intensity (*i.e.*, percentage of time spent on light, moderate, and vigorous intensity) were calculated over the last 20 years before study participation.

115

### 116 Experimental design

Participants visited our laboratory on two separate days during this cross-sectional study. On Day 1, participants were medically screened for eligibility, followed by an incremental maximal cycling test. On Day 2, participants underwent a comprehensive assessment of vascular function and structure using non-invasive echo-Doppler ultrasound techniques.

121

#### 122 Experimental measures

### 123 Day 1: Screening + Incremental maximal cycling test

124 Screening. A physician medically screened participants by taking a detailed medical history, physical examination, and 12-lead electrocardiogram. Cardiac medical history of the post-MI 125 participants was retrieved from their medical history reports, which encompassed the clinical 126 127 diagnosis of the MI, details of the size and location of the MI, and treatment strategy. To gain insight in the cardiovascular risk profile of the participants, we calculated the Lifetime Risk Score 128 (LRS) for a 30-year risk prediction of cardiovascular disease mortality (4). Parameters taken into 129 account for the LRS were age, systolic blood pressure, total cholesterol, physical fitness level, and 130 body mass index. 131

132

*Incremental maximal cycling test.* Peak oxygen uptake (VO<sub>2</sub>peak, mLO<sub>2</sub>/min/kg) of the participants
was determined via an incremental maximal cycling test. Heart rate was continuously measured via
a 12 lead-electrocardiogram. Oxygen uptake (VO<sub>2</sub> [ml/min]), carbon dioxide output (VCO<sub>2</sub>

[ml/min]), and respiratory exchange ratio (RER) were measured via a gas analyser (CPET, Cosmed v9.1b, Rome, Italy). Lactate concentration (mmol/L) was measured via a capillary blood sample taken one-and-a-half minute after cessation of the test with the *Lactate Pro*<sup>TM</sup>2 (*Arkray*, type LT-1730, Kyoto, Japan).

140

141 Day 2: Vascular function and structure

142 All measurements were performed according to recent guidelines for vascular assessment and in a 143 temperature-controlled room (34) using a T3000 ultrasound system (Terason Teratech Corporation, 144 Boston, United States) equipped with a 10-MHz 12L5 linear transducer. Continuous Doppler 145 velocity was obtained using a position insonification angle of  $<60^{\circ}$  (6). Participants followed a >6hfasting period, ≥18h abstinence from caffeine, alcohol, vitamin supplements, and performed no 146 vigorous physical activity at least 24h before the test. Measurements began after a resting period in 147 the supine position for at least 15 minutes (34). Subsequently, heart rate and blood pressure were 148 manually assessed using a sphygmomanometer. Blood samples were obtained after the vascular 149 150 measurements from the antecubital vein for the analysis of blood glucose, and traditional cardiovascular risk markers (cholesterol, HDL, LDL, triglycerides, and glycated hemoglobin 151 152 [HbA1c]).

153

*Brachial artery endothelium-dependent flow-mediated dilatation (FMD).* The FMD (an index of endothelial function) of the brachial artery was measured by positioning the Echo-Doppler probe on the brachial artery. A pneumatic cuff (E20 rapid cuff inflator, Hokanson, Bellevue, United States) was placed on the right forearm, distally from the imaged artery. Diameter and flow velocity were recorded at the baseline during one-minute, followed by 5 minutes of ischemia by inflating the pneumatic cuff at 220 mmHg. Diameter and blood velocity recordings resumed 30 seconds before deflating the cuff and continued for 3 minutes thereafter, during the reperfusion (34).

*Brachial artery conduit artery vasodilatory capacity (CADC).* After a 20-minute resting period, the CADC (an index of arterial structure) was measured using the same equipment. The pneumatic cuff was inflated to 220 mmHg on the right upper arm, proximal from the imaged artery, for 5 minutes. Participants performed handgrip exercise from minute one until minute four (one-second contraction/one-second relaxation) at ~30 newton during the ischemic period. Diameter and blood velocity recordings resumed 30 seconds before deflating the cuff and continued for 3 minutes thereafter, to detect peak flow and peak diameter (26).

169

Brachial artery endothelium-independent dilatation. After another 20-minute rest, the vasodilator response to glyceryl trinitrate mediated vasodilatation (GTN; an index of vascular smooth muscle function) was measured. After recording baseline brachial artery diameter across 1-min, a single dose (400 μg) sublingual GTN (nitric oxide donor) was administered. Recording of diameter and blood velocity of the artery continuous 8 minute thereafter (14).

175

176 FMD, CADC, and GTN dilation were analyzed by custom-designed edge-detection and wall tracking software written in LabVIEW (LabVIEW 6.02, National Instruments, Austin, United 177 States) as described elsewhere (5). Briefly, from B-mode a region of interest (ROI) was drawn to 178 179 calibrate the artery diameter. Within this ROI a pixel-density algorithm automatically identified the vessel wall. For the calibration of the blood flow velocity another ROI was drawn around the 180 Doppler waveform. Baseline diameter was calculated as the mean of data acquired during one-181 minute baseline recording, preceding cuff inflation. Peak diameter and peak of blood flow velocity 182 was detected during three minutes of reperfusion. Brachial artery FMD, CADC, and GTN response 183 184 were calculated as the relative difference in peak diameter and baseline diameter.

185

186

#### 188 Pulse wave velocity: vascular stiffness

As an index for vascular stiffness, central and peripheral pulse wave velocity were measured using a 189 three-lead electrocardiogram and an Echo-Doppler ultrasound machine (Waki Doppler, Atys 190 191 Medical, Soucieu en Jarrest, France) at the left carotid artery, right common femoral artery, and radial artery. The distances were measured between sternal notch and site of measurement for the 192 carotid artery and between radial artery and common femoral artery via the umbilicus (20). At least 193 194 10 cardiac cycles were recorded for analyses. Based on the interval between the R-wave on the 195 electrocardiogram and onset of the Doppler waveform, central and peripheral pulse wave velocities were calculated in Matlab (MATLAB and Statistics Toolbox Release R2014, The MathWorks, Inc., 196 197 Natick, United States).

198

### 199 Conduit artery intima-media thickness

Intima-media thickness (IMT) of the left common carotid, brachial, and superficial femoral artery 200 were recorded using the same ultrasound machine. Image sequences of  $\geq 10$  seconds were recorded 201 1.5 to 2.5 cm distally of the bifurcation of the common carotid and superficial artery, while having 202 the vessel in a longitudinal imaging plane. Diameter and wall thickness were collected from two 203 distinct angles. Analysis was performed using custom-designed off-line edge-detection and wall-204 tracking software written in LabVIEW (LabVIEW 6.02, National Instruments, Austin, United 205 States). This DICOM-based software is largely independent of investigator bias and has been 206 previously described in detail (28, 29). Briefly, each recording was converted to a DICOM file at a 207 frame rate of 30 Hz. Detection of the far wall media-adventitia interface was performed on every 208 frame selected. The mean diameter and wall thickness were calculated by using the formula: (1/3 x)209 210 systolic diameter or wall thickness) +  $(2/3 \times \text{diastolic diameter or wall thickness})$ . Additionally, to correct for differences in vascular tone between measurements wall:lumen-ratio was calculated. All 211 files were analyzed blinded by an independent researcher. 212

### 214 Power calculation and statistical analysis

Based on anticipated difference in %FMD between study groups of 3.5% with a SD of 2.4 (6, 10), a power of 90% and alpha 5% significance level, we calculated that 18 subjects per group should be included. To correct for possible drop-out, we included 20 subjects per study group.

218

219 Characteristics of the participants and vascular function and vascular structure were summarized 220 with means and standard deviations or median and interquartile range (IQR), when appropriate. 221 Categorical data were analysed using the Fisher's exact test. Parameters were checked for normality using a Shapiro-Wilk test. Non-normal data were Ln-transformed before the statistical analysis. 222 223 Data that could not be transformed into Gaussian distribution were analysed using nonparametric tests. For aim 1 and 2, differences between veteran athletes and sedentary peers, either with or 224 without a history of MI, were assessed using an independent Student's t or Mann-Whitney U test. 225 when appropriate. All statistical analyses were performed using SPSS 21.0 software (IBM Corp. 226 Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). 227 228 Statistical significance was assumed at p < 0.05 (two-sided).

229

## 230 **RESULTS**

#### 231 Veteran athletes vs. sedentary controls

ATH had a lower body weight and body mass index compared to SED, whilst no differences were 232 present for age, height, and mean arterial pressure (Table 1). ATH performed significantly more 233 exercise per week compared to SED (7.1 hours/weeks [5.8-11.9] vs. 0.5 hours/weeks [0.0-1.4], 234 P<0.01), respectively. ATH performed most of their activities at a moderate intensity (66%), 235 followed by vigorous (33%) and light intensity (1%). ATH reached a higher VO<sub>2</sub>peak and power 236 output during the incremental exercise test compared to SED (Table 1). ATH showed higher HDL 237 and lower LDL and triglyceride levels compared to SED, whilst no differences were found for 238 HbA1c and cholesterol (Table 1). As a consequence of these differences, ATH demonstrated a 239

- 240 lower lifetime risk score compared to SED (Table 1). Participants with a positive family history of
- cardiovascular diseases did not differ between ATH (n=8, 44%) and SED (n=6, 33%), P=0.73.

242

*Vascular function + structure.* Whilst ATH and SED did not differ in brachial diameter and SR<sub>AUC</sub>, the FMD was lower in ATH compared to SED (Table 2). We found no differences between ATH and SED for CADC or GTN response, whereas FMD/GTN ratio was significantly lower in ATH compared to SED (Table 2). ATH demonstrated a lower central and peripheral pulse wave velocity (*i.e.*, higher vascular compliance) compared to SED (Figure 1). No differences between groups were found for IMT, diameter, and wall:lumen-ratio of the carotid and brachial artery, whilst femoral artery IMT and wall:-lumen-ratio was smaller in ATH compared to SED (Table 2).

250

#### 251 Veteran post-MI athletes vs. sedentary post-MI controls

ATH+MI had a lower body weight and body mass index compared to SED+MI (Table 3). ATH+MI 252 performed significantly more exercise per week compared to SED+MI (5.7 hours/week [4.9-9.4] vs. 253 254 0.2 hours/week [0.0-1.2], P<0.01), respectively. ATH+MI performed most of their activities at a moderate intensity (63%), followed by vigorous (34%) and light intensity (3%). Intensity patterns 255 did not differ between ATH and ATH+MI. ATH+MI reached a higher VO<sub>2</sub>peak and power output 256 257 during the incremental exercise test compared to SED+MI (Table 3). Cholesterol, HDL, and LDL levels did not differ between ATH+MI and SED+MI, but ATH+MI had lower triglyceride levels 258 compared to SED+MI (Table 3). ATH+MI demonstrated a lower lifetime risk score compared to 259 SED+MI (Table 3). Participants with a positive family history of cardiovascular diseases did not 260 differ between ATH+MI (n=15, 75%) and SED+MI (n=15, 79%), P=1.00. 261

No differences were observed in extent and location of the MI between groups (Table 4). Treatment strategy (surgical and rehabilitation) did not differ between groups (Table 4). Six SED+MI needed an elective percutaneous coronary intervention (PCI) and two reported a recurrent MI, whereas none of the ATH+MI needed an elective PCI or reported a recurrent MI. The use of anticoagulants, lipid lowering and antihypertensive agents did not differ between groups, whilst fewer ATH+MI
used ACE-inhibitors (Table 4).

268

*Vascular function* + *structure*. We found no significant differences between ATH+MI and SED+MI for brachial artery diameter, FMD, CADC, GTN, or GTN/FMD ratio (Table 5). We also found no differences between groups for central or peripheral pulse wave velocity (Figure 1). We found no significant differences in carotid, brachial and femoral artery IMT, diameter and wall:lumen-ratio between groups.

274

# 275 **DISCUSSION**

276 We present the following findings. First, in line with our hypothesis, some markers of vascular 277 function (i.e., pulse wave velocity) and structure (i.e., femoral IMT and wall:lumen-ratio) were significantly better in asymptomatic veteran athletes compared to their sedentary peers, potentially 278 279 contributing to the benefits of lifelong exercise. Second, in contrast with our hypothesis, we found no differences in vascular function or structure between veteran post-MI athletes and sedentary 280 post-MI controls, which may be a consequence of pharmaceutical strategies. Third, veteran athletes 281 with or without a history of MI had a significantly better cardiovascular risk profile compared to 282 their sedentary peers. Furthermore, veteran post-MI athletes reported no secondary events, which 283 contrasts the 8 events that occurred in the sedentary post-MI controls. Taken together, our findings 284 indicate that veteran post-MI athletes do not have a superior vascular function and structure 285 compared to their sedentary peers, whilst benefits of lifelong exercise relate to better cardiovascular 286 risk profile and a lower occurrence in secondary events. 287

288

#### 289 Impact of lifelong exercise on vascular function and structure: asymptomatic individuals

Our results support the hypothesis that benefits of lifelong exercise training go beyond traditional
risk factors (19) and improves functional and structural aspects of the vascular system. For example,

femoral IMT was significantly smaller in veteran athletes compared to sedentary controls, which is in line with previous studies that report that regular exercise training is associated with a smaller conduit artery wall thickness (25, 30). Related to functional characteristics of the vasculature, we found that veteran athletes have a higher central and peripheral vascular compliance compared to sedentary controls. This observation confirms previous studies which demonstrated that exercise training improves arterial compliance (3, 33).

298

299 Somewhat conflicting with the observations related to central and peripheral compliance, we observed a significantly lower FMD in veteran athletes compared to their sedentary peers. A 300 301 previous study demonstrated that young healthy athletes had a lower FMD compared to their sedentary peers (5.1% vs. 6.0% respectively) (16). The authors suggested that the lower FMD in 302 young athletes might relate to inherent structural changes in the artery and the interaction between 303 artery structure and function (16). In the present study, however, baseline diameter did not differ 304 between athletes and sedentary controls. It is therefore unlikely that structural differences explain 305 the lower FMD responses among athletes. Also differences in smooth muscle cell sensitivity for 306 nitric oxide cannot explain our results, since the GTN response did not differ between groups 307 (ATH: 17.1%±6.7 vs. SED: 15.1±5.4, P=0.33). Alternatively, an interaction between vasodilator 308 309 mechanisms and the autonomic sympathetic nervous system may contribute to a lower FMD in athletes (16). Athletes typically exhibit altered autonomic balance, which may contribute to 310 attenuated conduit artery endothelium-dependent responses to elevation in shear (16). However, 311 future studies are necessary to explore this hypothesis. Our findings indicate that endothelial flow-312 mediated vasodilation is lower in veteran athletes compared to their sedentary peers, whereas 313 314 differences are not simply related to structural differences or smooth muscle sensitivity between 315 groups.

316

#### 318 Impact of lifelong exercise on vascular function and structure: post-MI individuals

Although a history of MI is associated with impairment in cardiovascular risk and vascular 319 320 function, regular exercise training is known to improve cardiovascular risk and vascular function. 321 However, in the present study no differences in vascular function and structure were found between veteran post-MI athletes and sedentary post-MI peers. A possible explanation for these unexpected 322 observations may relate to the extent of the MI. However, we observed no differences in cardiac 323 enzyme markers, location of the MI and duration since MI between ATH-MI and SED-MI. 324 325 Alternatively, previous studies that revealed an impaired endothelial function in post-MI patients 326 observed these effects within 1-12 months following MI (1, 10), whereas we measured the 327 endothelial function after 7±5 years following MI. Since the endothelium recovers during the first months post-MI (39), our results may be partly explained by the long time since MI and/or bias in 328 selecting 'healthy' post-MI patients given the long time since MI. Finally, prescription of 329 medication after MI may contribute to our observations, especially since several cardiac 330 medications directly improve endothelial function (23, 41). Antihypertensive agents most likely 331 decrease in oxidative stress and increase nitric oxide bioavailability (23), whereas statins are 332 associated with an improvement in endothelial function and FMD (41). Therefore, the combination 333 of the prolonged post-MI period and use of cardiac medications may ameliorate endothelial 334 function and structure in both post-MI groups. This might explain absence of differences in vascular 335 function and structure between post-MI athletes and sedentary peers. 336

337

Despite the absence of differences in vascular function and marginal differences in cardiovascular risk factors, veteran post-MI athletes showed a better cardiovascular lifetime risk score compared to their sedentary post-MI peers. The higher cardiorespiratory fitness in athletes was the major contributor to the better risk score among athletes. Cardiorespiratory fitness is strongly related with reduced risk for morbidity and mortality as well it mitigates the risk of a second cardiac event (7, 9). Although, our study was not powered to investigate the relation between lifelong exercise and secondary events following MI, our results indicated that post-MI athletes reported fewer complications (elective PCI or recurrent MI) after the MI compared to their sedentary post-MI peers. Alternative benefits of regular exercise training may relate to an improvement in circulating hormones, endothelial progenitor cells, and/or (exercise) preconditioning of the vasculature (11, 31, 37). Future research is warranted to elucidate benefits of exercise training in more detail to close the 'risk factor gap' in cardiovascular disease (19).

350

#### 351 LIMITATIONS

This study was inherent to some limitations. First, the cross-sectional design of our study makes it 352 353 difficult to give detailed view of the development of vascular function and structure across time and study the impact of a MI. Second, post-MI participants were allowed to take their medication before 354 the measurements due to ethical considerations. Medication usage might influence the results of the 355 vasculature. However, since both post-MI groups took their medication, we believe it likely that the 356 medication effect on the vasculature did not influenced our major observations regarding the 357 358 comparison between post-MI groups. Finally, most of our veteran athletes performed primarily lower limb endurance exercises, such as running and cycling. Therefore, it is difficult to translate 359 our results to other types of exercise training, especially since resistance exercise training may be of 360 361 special interest in older populations.

362

#### 363 CONCLUSION

The present study indicates that some markers of vascular function (*i.e.*, compliance) and structure (*i.e.*, femoral IMT and wall:lumen-ratio) were significantly better in asymptomatic veteran athletes compared to their sedentary peers. Whilst these observations are in line with previous reports and emphasise the benefits of regular exercise, we unexpectedly found no differences in vascular function and structure between veteran post-MI athletes and sedentary post-MI controls. Whilst medication use may contribute to these findings, regular exercise training in veteran post-MI athletes was still associated with significantly better cardiovascular risk profile and lower
 occurrence of secondary events compared to sedentary post-MI controls.

372

## 373 Acknowledgments

## 374 Conflicts of Interest and Source of Funding

TMHE is financially supported by a European Commission Horizon 2020 grant [Marie Sklodowska-Curie Fellowship 655502]. DHJT is financially supported by the Netherlands Heart Foundation (2009T064). The remaining authors report no conflicts of interest that are directly relevant to the content of this manuscript.

379

380 The results of the present study do not constitute endorsement by ACSM. The results of the study 381 are presented clearly, honestly, and without fabrication, falsification, or inappropriate data 382 manipulation.

383

# 385 **REFERENCES**

| 386 | 1. | Agewall S, Henareh L, Kublickiene K. Endothelial function in conduit and resistance |
|-----|----|---|
| 387 |    | arteries in men with coronary disease. Atherosclerosis. 2006;184(1):130-6.          |

3882.Ainsworth BE, Haskell WL, Herrmann SD et al. 2011 Compendium of Physical Activities:

a second update of codes and MET values. *Medicine and science in sports and exercise*.

390 2011;43(8):1575-81.

- Ashor AW, Lara J, Siervo M, Celis-Morales C, Mathers JC. Effects of exercise modalities
   on arterial stiffness and wave reflection: a systematic review and meta-analysis of
   randomized controlled trials. *PloS one*. 2014;9(10):e110034.
- Berry JD, Dyer A, Cai X et al. Lifetime risks of cardiovascular disease. *The New England journal of medicine*. 2012;366(4):321-9.
- Black MA, Cable NT, Thijssen DH, Green DJ. Importance of measuring the time course of
  flow-mediated dilatation in humans. *Hypertension*. 2008;51(2):203-10.
- Black MA, Cable NT, Thijssen DH, Green DJ. Impact of age, sex, and exercise on brachial
   artery flow-mediated dilatation. *American journal of physiology. Heart and circulatory physiology*. 2009;297(3):H1109-16.
- 401 7. Blair SN, Kampert JB, Kohl HW, 3rd et al. Influences of cardiorespiratory fitness and other
  402 precursors on cardiovascular disease and all-cause mortality in men and women. *JAMA*.
  403 1996;276(3):205-10.
- 8. Brockow T, Conradi E, Ebenbichler G, Michalsen A, Resch KL. The role of mild systemic
  heat and physical activity on endothelial function in patients with increased cardiovascular
  risk: results from a systematic review. *Forschende Komplementarmedizin*. 2011;18(1):24-

407

30.

408 9. Corra U, Piepoli MF, Carre F et al. Secondary prevention through cardiac rehabilitation:
409 physical activity counselling and exercise training: key components of the position paper

- from the Cardiac Rehabilitation Section of the European Association of Cardiovascular 410 Prevention and Rehabilitation. European heart journal. 2010;31(16):1967-74. 411 412 10. Dalli E, Segarra L, Ruvira J et al. Brachial artery flow-mediated dilation in healthy men, 413 men with risk factors, and men with acute myocardial infarction. Importance of occlusioncuff position. Rev Esp Cardiol. 2002;55(9):928-35. 414 415 11. DeVan AE, Umpierre D, Lin HF et al. Habitual resistance exercise and endothelial 416 ischemia-reperfusion injury in young adults. Atherosclerosis. 2011;219(1):191-3. 417 12. Di Francescomarino S, Sciartilli A, Di Valerio V, Di Baldassarre A, Gallina S. The effect of 418 physical exercise on endothelial function. Sports medicine. 2009;39(10):797-812. 419 13. Garber CE, Blissmer B, Deschenes MR et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, 420 musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for 421 prescribing exercise. Medicine and science in sports and exercise. 2011;43(7):1334-59. 422 Gilbert SE, Tew GA, Bourke L, Winter EM, Rosario DJ. Assessment of endothelial 423 14. 424 dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer. *Experimental physiology*. 2013;98(9):1401-10. 425 15. Goto C, Higashi Y, Kimura M et al. Effect of different intensities of exercise on 426 427 endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation. 2003;108(5):530-5. 428
  - 429 16. Green DJ, Rowley N, Spence A et al. Why isn't flow-mediated dilation enhanced in
    430 athletes? *Medicine and science in sports and exercise*. 2013;45(1):75-82.
  - 431 17. Green DJ, Spence A, Rowley N, Thijssen DH, Naylor LH. Vascular adaptation in athletes:
    432 is there an 'athlete's artery'? *Experimental physiology*. 2012;97(3):295-304.
  - 433 18. Haram PM, Kemi OJ, Wisloff U. Adaptation of endothelium to exercise training: insights
  - 434 from experimental studies. *Frontiers in bioscience : a journal and virtual library*.
  - 435 2008;13:336-46.

- 436 19. Joyner MJ, Green DJ. Exercise protects the cardiovascular system: effects beyond
  437 traditional risk factors. *J Physiol*. 2009;587(Pt 23):5551-8.
- Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness:
  methodological issues and clinical applications. *European heart journal*. 2006;27(21):2588605.
- 441 21. Maessen MF, Verbeek AL, Bakker EA, Thompson PD, Hopman MT, Eijsvogels TM.
- 442 Lifelong Exercise Patterns and Cardiovascular Health. *Mayo Clinic proceedings*.
  443 2016;91(6):745-54.
- 444 22. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering
- of acute myocardial infarction by heavy physical exertion. Protection against triggering by
- regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. *The New England journal of medicine*. 1993;329(23):1677-83.
- Miyamoto M, Kotani K, Ishibashi S, Taniguchi N. The effect of antihypertensive drugs on
  endothelial function as assessed by flow-mediated vasodilation in hypertensive patients. *International journal of vascular medicine*. 2012;2012:453264.
- 451 24. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of
  452 cardiovascular events: potential mediating mechanisms. *Circulation*. 2007;116(19):2110-8.
- 453 25. Moreau KL, Donato AJ, Seals DR et al. Arterial intima-media thickness: site-specific
- associations with HRT and habitual exercise. *American journal of physiology. Heart and circulatory physiology.* 2002;283(4):H1409-17.
- 456 26. Naylor LH, Weisbrod CJ, O'Driscoll G, Green DJ. Measuring peripheral resistance and
- 457 conduit arterial structure in humans using Doppler ultrasound. *Journal of applied*
- 458 *physiology*. 2005;98(6):2311-5.
- 459 27. Nualnim N, Barnes JN, Tarumi T, Renzi CP, Tanaka H. Comparison of central artery
  460 elasticity in swimmers, runners, and the sedentary. *Am J Cardiol.* 2011;107(5):783-7.

| 461 | 28. | Potter K, Green DJ, Reed CJ et al. Carotid intima-medial thickness measured on multiple |
|-----|-----|---|
| 462 |     | ultrasound frames: evaluation of a DICOM-based software system. Cardiovascular          |
| 463 |     | ultrasound. 2007:5:29.  |

- 464 29. Potter K, Reed CJ, Green DJ, Hankey GJ, Arnolda LF. Ultrasound settings significantly alter arterial lumen and wall thickness measurements. Cardiovascular ultrasound. 2008;6:6.
- 466 30. Seals DR, Walker AE, Pierce GL, Lesniewski LA. Habitual exercise and vascular ageing. J
- Physiol. 2009;587(Pt 23):5541-9. 467

465

31. Seeger JP, Lenting CJ, Schreuder TH et al. Interval exercise, but not endurance exercise, 468 prevents endothelial ischemia-reperfusion injury in healthy subjects. American journal of 469

470 physiology. Heart and circulatory physiology. 2015;308(4):H351-7.

- 32. Sofi F, Capalbo A, Cesari F, Abbate R, Gensini GF. Physical activity during leisure time 471
- 472 and primary prevention of coronary heart disease: an updated meta-analysis of cohort
- studies. European journal of cardiovascular prevention and rehabilitation : official journal 473
- 474 of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and 475 Cardiac Rehabilitation and Exercise Physiology. 2008;15(3):247-57.
- 476 33. Tanaka H, Dinenno FA, Monahan KD, Clevenger CM, DeSouza CA, Seals DR. Aging, habitual exercise, and dynamic arterial compliance. Circulation. 2000;102(11):1270-5. 477
- 478 34. Thijssen DH, Black MA, Pyke KE et al. Assessment of flow-mediated dilation in humans: a 479 methodological and physiological guideline. American journal of physiology. Heart and
- circulatory physiology. 2011;300(1):H2-12. 480
- Thijssen DH, Cable NT, Green DJ. Impact of exercise training on arterial wall thickness in 481 35. 482 humans. *Clinical science*. 2012;122(7):311-22.
- 483 36. Thijssen DH, Maiorana AJ, O'Driscoll G, Cable NT, Hopman MT, Green DJ. Impact of inactivity and exercise on the vasculature in humans. European journal of applied 484
- 485 physiology. 2010;108(5):845-75.

| 486 | 37. | Thijssen DH, Vos JB, Verseyden C et al. Haematopoietic stem cells and endothelial             |
|-----|-----|---|
| 487 |     | progenitor cells in healthy men: effect of aging and training. Aging Cell. 2006;5(6):495-503. |
| 488 | 38. | Thompson PD, Stern MP, Williams P, Duncan K, Haskell WL, Wood PD. Death during                |
| 489 |     | jogging or running. A study of 18 cases. JAMA. 1979;242(12):1265-7.                           |
| 490 | 39. | Vona M, Codeluppi GM, Iannino T, Ferrari E, Bogousslavsky J, von Segesser LK. Effects         |
| 491 |     | of different types of exercise training followed by detraining on endothelium-dependent       |
| 492 |     | dilation in patients with recent myocardial infarction. Circulation. 2009;119(12):1601-8.     |
| 493 | 40. | Walther G, Nottin S, Karpoff L, Perez-Martin A, Dauzat M, Obert P. Flow-mediated              |
| 494 |     | dilation and exercise-induced hyperaemia in highly trained athletes: comparison of the upper  |
| 495 |     | and lower limb vasculature. Acta physiologica. 2008;193(2):139-50.                            |
| 496 | 41. | Zhang L, Gong D, Li S, Zhou X. Meta-analysis of the effects of statin therapy on endothelial  |
| 497 |     | function in patients with diabetes mellitus. Atherosclerosis. 2012;223(1):78-85.              |

# 500 FIGURES

A. Veteran athletes vs. sedentary controls



**Figure 1.** Arterial stiffness of (A) athletes (circles) vs. sedentary controls (squares) and (B) athletes+MI (triangles) and sedentary controls+MI (diamonds) of the central pulse wave velocity and peripheral pulse wave velocity. Athletes had lower central and peripheral pulse wave velocity, indicating that athletes had decreased vascular stiffness (*i.e.*, higher vascular compliance) compared to sedentary controls. No differences were observed in vascular stiffness between post-MI groups. Data is presented as median and interquartile range.

cPWV: central pulse wave velocity, pPWV: peripheral pulse wave velocity

501

**Table 1.** Characteristics of the athletes (ATH) *vs.* sedentary (SED) controls. Data is presented as mean and standard deviation or median and interquartile range. P-value refers to an *independent Student's t* test or *Mann-Whitney U* test.

|  | ATH<br><i>n</i> =18 | $\begin{array}{c} \text{SED} \\ n=18 \end{array}$ | p value |
|--|---------------------|---|---------|
| CHARACTERISTICS                                  |                     |   |         |
| Age (years)                                      | 61±7                | 58±7  | 0.29    |
| Height (cm)                                      | 179±8               | 181±6   | 0.31    |
| Weight (kg)                                      | 74±8                | 87±10   | < 0.01  |
| Body Mass Index (kg/m <sup>2</sup> )             | 23.6 (21.1-24.9)    | 26.7 (25.0-27.4)                                  | < 0.01  |
| Mean arterial pressure (mmHg)                    | 98 (90-106)         | 103 (93-107)                                      | 0.70    |
| Systolic Blood Pressure (mmHg)                   | 134 (122-142)       | 136 (124-146)                                     | 0.53    |
| Diastolic Blood Pressure (mmHg)                  | 84±10               | 84±10   | 0.92    |
| Resting Heart Rate (beats/min)                   | 52±6                | 64±11   | < 0.01  |
| Exercise time (hours/week)                       | 7.1 (5.8-11.9)      | 0.5 (0.0-1.4)                                     | < 0.01  |
| INCREMENTAL EXERCISE TEST                        |                     |   |         |
| VO2peak (mL/min/kg)                              | $48.0 \pm 8.5$      | 32.8±5.2  | < 0.01  |
| Maximal heart rate (beats/min)                   | 165±13              | 171±15  | 0.29    |
| RER (ratio: VCO <sub>2</sub> / VO <sub>2</sub> ) | 1.13 (1.06-1.17)    | 1.08 (1.05-1.14)                                  | 0.020   |
| Lactate (mmol/L)                                 | 8.9 (11.6-12.3)     | 11.1 (9.4-12.8)                                   | 0.77    |
| Power Output (W)                                 | 319±58              | 209±46  | < 0.01  |
| CARDIOVASCULAR RISK PROFI                        | LE                  |   |         |
| Lifetime risk score                              | 4.0 (1.7-7.0)       | 6.9 (4.4-10.2)                                    | < 0.05  |
| Glucose (mmol/L)                                 | 4.6 (4.4-5.0)       | 4.7 (4.4-4.9)                                     | 0.66    |
| HbA1c (mmol/mol)                                 | 35.5 (34.4-38.3)    | 35.5 (35.5-38.3)                                  | 0.53    |
| Cholesterol (mmol/L)                             | $5.4 \pm 0.8$       | 5.9±0.9   | 0.07    |
| HDL (mmol/L)                                     | 1.8±0.3             | 1.4±0.3   | < 0.01  |
| LDL (mmol/L)                                     | 3.3±0.8             | 4.0±0.8   | < 0.05  |
| Triglycerides (mmol/L)                           | 0.8 (0.7-1.2)       | 1.3 (1.0-2.4)                                     | < 0.01  |

RER: Respiratory Exchange Ratio; HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; LDL: low-density lipoprotein.

**Table 2.** Vascular function and structure of the athletes (ATH) and sedentary (SED) controls. Data is presented as mean and standard deviation or median and interquartile range (IQR). P-value refers to an *independent Student's t* test or *Mann-Whitney U* test.

|                        | ATH<br><i>n</i> =18 | $\sum_{n=18}^{\text{SED}}$ | p value |  |  |  |
|------------------------|---------------------|----------------------------|---------|--|--|--|
| VASCULAR FUNCTION      |                     |                            |         |  |  |  |
| FLOW MEDIATED DILATION |                     |                            |         |  |  |  |
| Baseline diameter (mm) | 4.3 (3.9-4.9)       | 4.4 (4.3-4.5)              | 0.65    |  |  |  |
| Peak dilation (%)      | 3.8±1.7             | $6.4 \pm 2.8$              | < 0.01  |  |  |  |
| Shear Rate (AUC)       | 21177 (14041-31869) | 18251 (12830-23160)        | 0.34    |  |  |  |
| CONDUIT ARTERY VASO    | DILATORY CAPACITY   |                            |         |  |  |  |
| Baseline diameter (mm) | 4.4±0.6             | 4.3±0.6                    | 0.84    |  |  |  |
| Peak dilation (%)      | 16.0±4.9            | 15.2±8.9                   | 0.75    |  |  |  |
| Shear Rate (AUC)       | 32380±10375         | 34566±13973                | 0.61    |  |  |  |
| GLYCERYL TRINITRATE    | DILATATION          |                            |         |  |  |  |
| Baseline diameter (mm) | 4.2±0.6             | $4.4 \pm 0.8$              | 0.43    |  |  |  |
| Peak dilation (%)      | 17.1±6.7            | 15.1±5.4                   | 0.33    |  |  |  |
| FMD / GTN ratio        | 0.23 (0.15-0.30)    | 0.40 (0.25-0.69)           | < 0.01  |  |  |  |
| VASCULAR STRUCTURE     |                     |                            |         |  |  |  |
| CAROTID ARTERY         |                     |                            |         |  |  |  |
| IMT (mm)               | 0.69 (0.58-0.81)    | 0.71 (0.65-0.86)           | 0.16    |  |  |  |
| Diameter (mm)          | 6.4 (5.8-6.7)       | 6.8 (6.4-7.3)              | 0.07    |  |  |  |
| wall:lumen-ratio       | 0.11 (0.09-0.13)    | 0.11 (0.10-0.12)           | 0.79    |  |  |  |
| BRACHIAL ARTERY        |                     |                            |         |  |  |  |
| IMT (mm)               | $0.44 \pm 0.11$     | $0.47 \pm 0.11$            | 0.41    |  |  |  |
| Diameter (mm)          | 4.0 (3.8-4.3)       | 4.4 (3.8-4.8)              | 0.13    |  |  |  |
| wall:lumen-ratio       | 0.11 (0.09-0.13)    | 0.10 (0.09-0.11)           | 0.84    |  |  |  |
| FEMORAL ARTERY         |                     |                            |         |  |  |  |
| IMT (mm)               | 0.59 (0.52-0.65)    | 0.64 (0.58-0.71)           | < 0.05  |  |  |  |
| Diameter (mm)          | 7.3±1.4             | 6.9±0.7                    | 0.23    |  |  |  |
| wall:lumen-ratio       | 0.08 (0.06-0.09)    | 0.09 (0.08-0.11)           | 0.01    |  |  |  |

AUC: area under the curve; IMT: Intima-media thickness

505

**Table 3.** Characteristics of the post-MI athletes (ATH+MI) *vs.* sedentary post-MI (SED+MI) controls. Data is presented as mean and standard deviation or median and interquartile range. P-value refers to an *independent Student's t* test, *Mann-Whitney U* test, or *Fisher's exact* test.

|  | ATH+MI<br>n=20   | SED+MI<br>n=19   | p value |
|--|------------------|------------------|---------|
| CHARACTERISTICS                                  |                  |                  |         |
| Age (years)                                      | 60±6             | 61±5             | 0.44    |
| Height (cm)                                      | 176±5            | 176±6            | 0.72    |
| Weight (kg)                                      | 77±7             | 84±13            | < 0.05  |
| Body Mass Index (kg/m <sup>2</sup> )             | 24.5 (23.9-26.0) | 26.8 (24.3-28.6) | < 0.05  |
| Mean arterial pressure (mmHg)                    | 95 (93-100)      | 92 (88-101)      | 0.17    |
| Systolic Blood Pressure (mmHg)                   | 131 (126-142)    | 124 (114-136)    | 0.051   |
| Diastolic Blood Pressure (mmHg)                  | 79±9             | 77±11            | 0.49    |
| Resting Heart rate (beats/min)                   | 57±7             | 60±9             | 0.26    |
| Exercise time (hours/week)                       | 5.7 (4.9-9.4)    | 0.2 (0.0-1.2)    | < 0.01  |
| Post-MI time before study participation (years)  | 5 (3-10)         | 7 (4-10)         | 0.73    |
| INCREMENTAL EXERCISE TEST                        |                  |                  |         |
| VO <sub>2</sub> peak (mL/min/kg)                 | 40.9±5.5         | 29.7±6.0         | < 0.01  |
| Maximal heart rate (beats/min)                   | 164±15           | 146±18           | < 0.01  |
| RER (ratio: VCO <sub>2</sub> / VO <sub>2</sub> ) | 1.10 (1.07-1.15) | 1.08 (1.05-1.14) | 0.31    |
| Lactate (mmol/L)                                 | 10.5 (9.2-11.2)  | 11.5 (9.4-12.4)  | 0.19    |
| Power Output (W)                                 | 274±40           | 190±49           | < 0.01  |
| CARDIOVASCULAR RISK PROFILE                      |                  |                  |         |
| Lifetime risk score                              | 5.4 (3.3-8.6)    | 8.6 (6.2-12.8)   | < 0.05  |
| Glucose (mmol/L)                                 | 4.6 (4.5-5.0)    | 4.8 (4.4-5.0)    | 0.95    |
| HbA1c (mmol/mol)                                 | 36.6 (35.5-37.7) | 37.7 (37.4-40.2) | < 0.01  |
| Cholesterol (mmol/L)                             | 4.5±0.9          | $4.2 \pm 0.9$    | 0.25    |
| HDL (mmol/L)                                     | 1.6±0.4          | 1.4±0.3          | 0.08    |
| LDL (mmol/L)                                     | 2.6±0.8          | 2.3±0.7          | 0.22    |
| Triglycerides (mmol/L)                           | 0.9 (0.8-1.1)    | 1.2 (1.0-2.0)    | < 0.05  |

RER: Respiratory Exchange Ratio; HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; LDL: low-density lipoprotein.

507

**Table 4.** Cardiac medical history data of post-MI athletes (ATH+MI) *vs.* sedentary post-MI (SED+MI) controls. P-value refers to an independent *Student's t, Mann-Whitney U, or Fisher's exact test* (two-sided). Data is presented as mean and standard deviation or median and interquartile range.

|   |              | ATH+MI         |              | SED+MI         | <i>p</i> -value |
|---|--------------|----------------|--------------|----------------|-----------------|
| Post-MI time before study participation (years) |              | 5 (3-10)       |              | 7 (4-10)       | 0.73            |
| ENZYME MARKERS*                                 |              |                |              |                |                 |
| CK (u/L)  | <i>n</i> =17 | 775 (251-2029) | <i>n</i> =17 | 871 (422-2467) | 0.45            |
| CREAT (umol/L)                                  | <i>n</i> =14 | 87 (78-103)    | <i>n</i> =16 | 89 (77-93)     | 0.70            |
| AST (u/L)                                       | <i>n</i> =14 | 38 (26-135)    | <i>n</i> =15 | 84 (36-208)    | 0.22            |
| LDH (u/L)                                       | <i>n</i> =13 | 407 (335-638)  | <i>n</i> =14 | 422 (178-537)  | 0.52            |
| INFARCT LOCATION                                |              |                |              |                |                 |
| Anterior (n)                                    |              | 7 (35%)        |              | 10 (53%)       | 0.34            |
| Inferior (n)                                    |              | 7 (35%)        |              | 8 (42%)        | 0.75            |
| Non-STEMI (n)                                   |              | 6 (30%)        |              | 1 (5%)         | 0.09            |
| TREATMENT*                                      |              |                |              |                |                 |
| PCI (n [%])                                     |              | 18 (95%)       |              | 16 (94%)       | 1.00            |
| Thrombolytic therapy (n [%])                    |              | 1 (5%)         |              | 1 (6%)         | 1.00            |
| CARDIAC REHABILITATION                          |              |                |              |                |                 |
| Cardiac rehabilitation (n [%])                  |              | 13 (65%)       |              | 11 (79%)       | 0.47            |
| SECONDARY EVENTS                                |              |                |              |                |                 |
| Elective PCI (n)                                |              | 0 (0%)         |              | 6 (32%)        | < 0.01          |
| Recurrent MI (n)                                |              | 0 (0%)         |              | 2 (11%)        | 0.23            |
| MEDICATION                                      |              |                |              |                |                 |
| Anticoagulant (n)                               |              | 19 (95%)       |              | 19 (100%)      | 1.00            |
| Anti-platelet (n)                               |              | 18 (90%)       |              | 17 (89%)       | 1.00            |
| Vitamin K antagonist (n)                        |              | 1 (5%)         |              | 2 (11%)        | 0.61            |
| Antihypertensive agents (n)                     |              | 14 (70%)       |              | 18 (95%)       | 0.09            |
| ACE-inhibitor (n)                               |              | 5 (25%)        |              | 14 (74%)       | < 0.01          |
| AT1-antagonist (n)                              |              | 3 (15%)        |              | 3 (16%)        | 1.00            |
| Beta-blocker (n)                                |              | 8 (40%)        |              | 14 (74%)       | 0.05            |
| Diuretic (n)                                    |              | 1 (5%)         |              | 4 (21%)        | 0.18            |
| Calcium channel blockers (n)                    |              | 1 (5%)         |              | 0 (0%)         | 1.00            |
| Lipid lowering agents (n)                       |              | 16 (80%)       |              | 19 (100%)      | 0.11            |
| Statins (n)                                     |              | 16 (80%)       |              | 18 (95%)       | 0.34            |

\*Based on a sub sample; hospital data not available

MI: myocardial infarction; PCI: Percutaneous coronary intervention; CK: Creatine kinase; CREAT: Creatinine; ASAT: Aspartate transaminase; LDH: Lactate dehydrogenase; Non-STEMI: non-ST elevation acute coronary syndrome; ACE: angiotensin converting enzyme; AT: angiotensin.

**Table 5.** Vascular function and structure of the post-MI athletes (ATH+MI) and sedentary post-MI (SED+MI) controls. Data is presented as mean and standard deviation or median and interquartile range (IQR). P-value refers to an *independent Student's t* test or *Mann-Whitney U* test.

|                        | ATH+MI<br>n=20     | $\begin{array}{c} \text{SED+MI} \\ n=19 \end{array}$ | p value |
|------------------------|--------------------|--|---------|
| VASCULAR FUNCTION      |                    |  |         |
| FLOW MEDIATED DILAT    | ION                |  |         |
| Baseline diameter (mm) | 4.5 (4.1-4.8)      | 4.2 (3.7-4.6)  | 0.42    |
| Peak dilation (%)      | $4.0{\pm}1.9$      | 5.3±3.3  | 0.16    |
| Shear Rate (AUC)       | 16646 (9987-23701) | 16837 (12395-19196)                                  | 0.89    |
| CONDUIT ARTERY VASO    | DILATORY CAPACITY  |  |         |
| Baseline diameter (mm) | 4.4±0.5            | 4.3±0.6  | 0.77    |
| Peak dilation (%)      | 14.0±6.2           | 13.1±5.2   | 0.65    |
| Shear Rate (AUC)       | 31593±9054         | 31394±9546   | 0.95    |
| GLYCERYL TRINITRATE    | DILATATION         |  |         |
| Baseline diameter (mm) | 4.3±0.6            | 4.4±0.6  | 0.82    |
| Peak dilation (%)      | 16.0±6.2           | 13.8±4.8   | 0.23    |
| FMD / GTN ratio        | 0.23 (0.18-0.41)   | 0.35 (0.19-0.49)                                     | 0.19    |
| VASCULAR STRUCTURE     |                    |  |         |
| CAROTID ARTERY         |                    |  |         |
| IMT (mm)               | 0.79 (0.64-0.86)   | 0.77 (0.69-0.80)                                     | 0.64    |
| Diameter (mm)          | 6.9 (6.5-7.2)      | 6.5 (6.2-7.1)  | 0.17    |
| wall:lumen-ratio       | 0.11 (0.09-0.13)   | 0.12 (0.10-0.13)                                     | 0.26    |
| <b>BRACHIAL ARTERY</b> |                    |  |         |
| IMT (mm)               | $0.48 \pm 0.1$     | 0.46±0.11  | 0.47    |
| Diameter (mm)          | 4.2 (3.6-5.1)      | 4.2 (3.8-4.6)  | 0.69    |
| wall:lumen-ratio       | 0.11 (0.10-0.12)   | 0.11 (0.10-0.12)                                     | 0.71    |
| FEMORAL ARTERY         |                    |  |         |
| IMT (mm)               | 0.70 (0.65-0.82)   | 0.65 (0.56-0.71)                                     | 0.05    |
| Diameter (mm)          | $7.4 \pm 0.8$      | 6.9±0.9  | 0.10    |
| wall:lumen-ratio       | 0.10 (0.09-0.11)   | 0.10 (0.08-0.11)                                     | 0.60    |

AUC: area under the curve; IMT: Intima-media thickness

510